Abstract:Esophageal carcinoma (EC) ranks among the top six most prevalent malignancies worldwide with a recent surge in incidence. An innovative integrated omics technique is presented for discerning the two primary types of esophageal carcinoma (EC) AND Squamous cell carcinoma and adenocarcinoma. Utilizing The Cancer Genome Atlas (TCGA) data via Bioconductor, the research integrated DNA methylation and RNA expression analyses for esophageal cancer (ESCA). Key findings revealed DNA methylation’s pivotal role in ESCA progression and its potential as an early detection biomarker. Significant disparities in methylation patterns offered insights into the disease’s pathogenesis. A comparison with the TCGA Pan-Cancer dataset using Bioconductor tools enriched the understanding of ESCA genomics. Specifically, 131,220 hypomethylated probes were detected in tumors compared to 6,248 in healthy tissues. Additionally, 42,060 probe-gene pairs linked methylation variations to expression alterations, with 768 hypomethylated motifs identified. Thirteen of these motifs emerged as potential diagnostic markers. Transcription factor analyses spotlighted crucial regulators, including NFL3, ATF4, JUN, and CEBPG, revealing intricate regulatory networks in ESCA. Survival statistics further correlated clinical factors with patient longevity. This research recommends an innovative approach to identifying oesophageal abnormalities through DNA methylation and gene expression mechanisms. Research suggests DNA methylation may serve as an early detection biomarker, aiding in identifying esophagus cancer prior to more advanced stages. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial "N/A" ### Clinical Protocols ### Funding Statement The work is self funded. my country blongs to group B global assistant program. I am the author of the manucript and i will apply for research group which will cover all the publication fee. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Our research adhered to high ethical standards, having received approval from the Institutional Review Board (IRB). This work was supported by the Liaoning Province Rejuvenating Talents Plan (No: XLYC2002045), the Key R&D Program of Liaoning Province (No: 2019JH2/10300041), Scientific Research Project from the Department of Education of Liaoning Province (No. LJKZ0088 and LQN201906), the National Natural Science Foundation of China (No: 82003655) and Shenyang Science and Technology Project (No. 21-116-3-48 and RC210216). The research did not entail any conflicts of interest and all financial support. The data collected during this study will be made available upon request, following the guidelines set by MedRxiv for data sharing. Each author contributed significantly to the execution of this research and the preparation of the manuscript, underlining a collective commitment to ethical research and reporting practices. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Upon the acceptance of this manuscript for publication, the supporting data and associated code will be made publicly available on GitHub for the benefit of the research community. Interested researchers can access these resources at the following repository: .

Abstract LB249: Multi-omics cancer risk assessment of Barrett's esophagus with DNA methylation sequencing from endoscopic brush samples

Abstract 1679: Genome-wide Methylation Analysis in Barrett's Esophagus and Esophageal Adenocarcinoma

Abstract 3330: Development of a genome-wide multiomic atlas of early-stage lung cancer enables identification of novel methylation biomarkers for disease detection beyond TCGA

Methylated B3GAT2 and ZNF793 are potential detection biomarkers for Barrett's esophagus.

Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study.

Abstract 5019: Comprehensive pan-cancer analysis of cfDNA methylation marks in tumors reveals complex epigenetic regulatory circuits and diagnostic biomarkers

Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus.

Genome-wide Methylation Analysis Shows Similar Patterns in Barrett’s Esophagus and Esophageal Adenocarcinoma

Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis.

Abstract 5150: Multimodal analysis of plasma cell-free DNA methylome for sensitive multi-cancer detection

Unlocking Esophageal Carcinoma’s Secrets: an Integrated Omics Approach Unveils DNA Methylation As a Pivotal Early Detection Biomarker with Clinical Implications

Comprehensive analysis of differentially methylated regions in colorectal cancer (CRC).

Multi-omic characterization of genome-wide abnormal DNA methylation reveals diagnostic and prognostic markers for esophageal squamous-cell carcinoma

Abstract P5-06-05: Whole-genome bisulfite sequencing of single circulating tumor cells identifies cellular methylation heterogeneity in metastatic breast cancer

Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck®, a Non-Endoscopic Esophageal Cell Collection Device

Abstract 757: Integrating microbiome analysis and multi-modal data to identify high-risk population for esophageal adenocarcinoma

Algorithm Training and Testing for a Non-Endoscopic Barrett's Esophagus Detection Test in Prospective Multicenter Cohorts

Abstract P028: Methylation biomarkers for colorectal cancer early detection and survival prognostics impact gene expression and link to cancer-related biological pathways

Abstract 2427: The development of a tissue-agnostic genome-wide methylome enrichment MRD assay for applications across the cancer care continuum for head and neck malignancies

Abstract 3493: Read-level methylation pattern extraction for high-multiplex large-scale targeted NGS assay

Abstract LB109: Detection of high grade intraepithelial neoplasia in colorectal cancer using a new blood-based multiplex septin9 methylation assay